A mouse PDX clinical trial reveals broad efficacy of niraparib and vc-seco-DUBA anti-HER2 ADC SYD985 in HER2/neu expressing endometrial cancer
{{output}}
Introduction: Advanced and recurrent high-risk endometrial cancer (EC) frequently develops resistance to platinum-based chemotherapy, leaving patients with limited therapeutic options. Recent studies have shown that HER2 expressi... ...
